Skip to content
Peptidepedia

Liraglutide Results: Timeline, Before & After & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Results Timelines

Weeks 1 to 2 (0.6 to 1.2 mg): Initial appetite suppression is often noticeable within the first few days. Modest weight loss of 1 to 2 kg may occur, partly from reduced caloric intake and partly from fluid shifts. Nausea is most common during this period. Blood glucose improvements begin in patients with diabetes.

Weeks 3 to 8 (1.8 to 3.0 mg): As the dose reaches maintenance levels, appetite reduction becomes more consistent. Weight loss typically accelerates to 0.5 to 1.0 kg per week. Gastrointestinal side effects peak during dose escalation but begin to stabilize. Most patients achieve 3 to 5% weight loss by week 8.

Weeks 8 to 16 (3.0 mg): This period is clinically important for assessing response. Prescribing guidelines recommend evaluating whether 4% body weight has been lost by week 16. Early responders (those who lose 4%+ by this point) go on to achieve significantly greater total weight loss (average 10.8%) compared to non-responders (average 3.0%).

Weeks 16 to 56 (3.0 mg): Continued use produces progressive weight loss that typically plateaus between weeks 40 and 56. The SCALE Obesity and Prediabetes trial reported mean weight loss of 8.0% versus 2.6% with placebo at 56 weeks, with 33.1% of liraglutide-treated patients achieving 10% or greater weight loss.

Frequently Asked Questions

Both are GLP-1 receptor agonists made by Novo Nordisk. Liraglutide requires daily injections and produces average weight loss of 6 to 8%, while semaglutide is dosed weekly and delivers roughly 15% weight loss. Semaglutide's structural modifications give it a longer half-life (7 days vs 13 hours), making it more convenient and more potent.

Saxenda contains liraglutide 3.0 mg (daily injection) and Wegovy contains semaglutide 2.4 mg (weekly injection). In the head-to-head STEP 8 trial, Wegovy produced 15.8% weight loss compared to 6.4% with Saxenda over 68 weeks. Both are FDA-approved for chronic weight management.

Saxenda follows a 5-week titration schedule. Start at 0.6 mg daily for one week, then increase by 0.6 mg each week until reaching the maintenance dose of 3.0 mg daily. This gradual escalation minimizes gastrointestinal side effects. If a dose increase is not tolerated, delay escalation for an additional week.

The most frequent side effects are gastrointestinal: nausea (39%), diarrhea (21%), constipation (19%), and vomiting (16%). These are most pronounced during dose escalation and typically improve over several weeks. Serious but rare side effects include pancreatitis and gallbladder disease.

In the SCALE Obesity and Prediabetes trial, participants lost an average of 8% of body weight over 56 weeks with liraglutide 3.0 mg plus lifestyle changes, compared to 2.6% with placebo. About 33% of participants achieved 10% or greater weight loss. Early responders who lost 4% or more by week 16 went on to lose an average of 10.8%.

Liraglutide has the longest post-marketing safety record of any GLP-1 agonist, with data spanning over 15 years since its 2010 approval. The LEADER trial followed 9,340 patients for a median of 3.8 years and demonstrated cardiovascular benefits. A 3-year extension of the SCALE trial confirmed sustained weight loss and reduced progression to type 2 diabetes.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med. 2015;373(1):11-22.
  2. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311-322.
  3. Davies MJ, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes (SCALE Diabetes). JAMA. 2015;314(7):687-699.
  4. Wadden TA, et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy for Obesity in Primary Care (SCALE IBT). Obesity. 2020;28(3):529-536.
  5. Kelly AS, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117-2128.
  6. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155.
  7. Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA. 2022;327(2):138-150.
  8. Wadden TA, et al. Weight Maintenance and Additional Weight Loss With Liraglutide After Low-Calorie-Diet-Induced Weight Loss (SCALE Maintenance). Int J Obes. 2013;37(11):1443-1451.
  9. FDA Approval of Saxenda for Weight Management in Patients Aged 12 and Older (2020).
  10. Saxenda (liraglutide) Prescribing Information. Novo Nordisk. 2023.
  11. Victoza (liraglutide) Prescribing Information. Novo Nordisk. 2023.
←Read the full Liraglutide guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”